Traws Pharma enters stock purchase agreement with Roth Principal Investments
TRAW•Traws Pharma entered a stock purchase agreement with Roth Principal Investments on Oct. 23, 2026, that may allow it to sell up to $50 million in common stock.
1. Stock purchase agreement
Traws Pharma entered a stock purchase agreement with Roth Principal Investments on Oct. 23, 2026. A filing said the company may sell up to $50 million in common stock.
